0001575872-20-000204.txt : 20200729 0001575872-20-000204.hdr.sgml : 20200729 20200729111128 ACCESSION NUMBER: 0001575872-20-000204 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200729 FILED AS OF DATE: 20200729 DATE AS OF CHANGE: 20200729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DR REDDYS LABORATORIES LTD CENTRAL INDEX KEY: 0001135951 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15182 FILM NUMBER: 201056274 BUSINESS ADDRESS: STREET 1: 8-2-337, ROAD NO.3 BANJARA HILLS CITY: HYDERABAD STATE: K7 ZIP: 500-034 BUSINESS PHONE: 91 40 49002900 MAIL ADDRESS: STREET 1: 8-2-337, ROAD NO.3 BANJARA HILLS CITY: HYDERABAD STATE: K7 ZIP: 500-034 6-K 1 drr0238_6k.htm FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2020

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

______________

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION

We hereby furnish the United States Securities and Exchange Commission with copies of the following information about our public disclosures regarding our results of operations and financial condition for the quarter ended June 30,2020.

On July 29, 2020, we announced our results of operations for the quarter ended June 30, 2020. We issued a press release announcing our results under International Financial Reporting Standards (“IFRS”), IFRS Unudited Consolidated Financial Results, Ind AS Unudited Consolidated Financial Results with Limited Review report and Ind AS Unudited Standalone Financial Results with Limited Review report for the quarter June 30, 2020, a copy of which is attached to this Form 6-K as Exhibit 99.1 , 99.2 , 99.3 and 99.4 respectively.

We have also made available to the public on our web site, www.drreddys.com, the following: IFRS Unudited Consolidated Financial Results, Ind AS Unaudited Consolidated Financial Results and Ind AS Unaudited Standalone Financial Results for the quarter ended June 30, 2020.

Exhibits

Exhibit Number		Description of Exhibits

99.1		Press Release, “Dr. Reddy’s Q1 FY21 Financial Results”, July 29, 2020

99.2		IFRS Unaudited Consolidated Financial Results for the quarter ended June 30, 2020

99.3		Ind AS Unaudited Consolidated Financial Results for the quarter ended June 30, 2020

99.4		Ind AS Unaudited Standalone Financial Results for the quarter ended June 30, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)

Date: July 29, 2020	By:	/s/ Sandeep Poddar
		Name:	Sandeep Poddar
		Title:	Company Secretary

EX-99.1 2 drr0238_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

	CONTACT
DR. REDDY'S LABORATORIES LTD.	Investor relationS	Media relationS
8-2-337, Road No. 3, Banjara Hills,	AMIT AGARWAL	APARNA TEKURI
Hyderabad - 500034. Telangana, India.	amita@drreddys.com	aparnatekuri@drreddys.com
	(Ph: +91-40-4900 2135)	(Ph: +91-40-4900 2446)

Dr. Reddy’s Q1 FY21 Financial Results

Hyderabad, India, July 29, 2020: Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter ended June 30, 2020. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS).

Revenues

Rs. 4,418 Cr

[YoY: Up 15%; QoQ: Down 0.3%]

Gross Margin

56.0%

[Q1 FY20: 51.7%; Q4 FY20: 51.5%]

SG&A Expenses

Rs. 1,279 Cr

[YoY: Up 6%; QoQ: Up 5%]

R&D Expenses

Rs. 398 Cr

[9.0% of Revenues]

EBITDA*

Rs. 1,162 Cr

[YoY: Up 2%; QoQ: Up 16%]

Profit before Tax

Rs. 879 Cr

[19.9% of Revenues]

Profit after Tax

Rs. 579 Cr

[13.1% of Revenues]

* Q1 FY20 includes a settlement income of Rs. 346 Cr, adjusted for which the EBITDA YoY growth is 47%

Commenting on the results, Co-chairman & MD, G V Prasad said “the current quarter’s financial performance has been strong across all parameters. I am glad that we have been able to serve our patients well and ensured continuity of business operations despite the challenging times. We have started integration of the acquired business from Wockhardt and executed two important licencing arrangements for treatment options for COVID-19. Currently, we are working towards bringing both these drugs to multiple markets”.

All amounts in millions, except EPS

All US dollar amounts based on convenience translation rate of I USD = Rs. 75.53

Dr. Reddy’s Laboratories Limited and Subsidiaries

Consolidated Income Statement

	Q1 FY21						Q1 FY20						YoY			Q4 FY20						QoQ
Particulars	($)			(Rs.)			($)			(Rs.)			Gr %			($)			(Rs.)			Gr%
Revenues		585			44,175			509			38,435			15			587			44,318			(0	)
Cost of Revenues		257			19,420			246			18,576			5			285			21,510			(10	)
Gross Profit		328			24,755			263			19,859			25			302			22,808			9
Operating Expenses
Selling, General & Administrative expenses		169			12,786			160			12,065			6			161			12,177			5
Research and Development expenses		53			3,980			48			3,609			10			55			4,190			(5	)
Impairment of non-current assets																	0			7			(100	)
Other operating income		(2	)		(118	)		(50	)		(3,759	)		(97	)		(2	)		(168	)		(30	)
Results from operating activities		107			8,107			105			7,944			2			87			6,602			23
Net finance income		(8	)		(605	)		(5	)		(393	)		54			(6	)		(435	)		39
Share of profit of equity accounted investees		(1	)		(77	)		(2	)		(163	)		(53	)		(1	)		(105	)		(27	)
Profit before Income Tax		116			8,789			113			8,500			3			95			7,142			23
Income tax		40			2,996			25			1,872			60			(7	)		(500	)		(699	)
Profit for the period		77			5,793			88			6,628			(13	)		101			7,642			(24	)

Diluted Earnings Per Share (EPS)		0.46			34.86			0.53			39.91			(13	)		0.61			46.01			(24	)

As a % to Revenues	Q1 FY21		Q1 FY20		Q4 FY20
Gross Profit		56.0		51.7		51.5
SG&A		28.9		31.4		27.5
R&D		9.0		9.4		9.5
EBITDA		26.3		29.5		22.6
PBT		19.9		22.1		16.1
PAT		13.1		17.2		17.2

EBITDA Computation

	Q1 FY21						Q1 FY20						Q4 FY20
Particulars	($)			(Rs.)			($)			(Rs.)			($)			(Rs.)
Profit before Income Tax		116			8,789			113			8,500			95			7,142
Interest income (net)*		(4	)		(306	)		(3	)		(239	)		(1	)		(100	)
Depreciation		28			2,120			28			2,124			28			2,080
Amortization		14			1,020			13			958			12			885
Impairment		0			0			0			0			0			7
EBITDA		154			11,622			150			11,343			133			10,013

* Includes income from Investments

All amounts in millions, except EPS

All US dollar amounts based on convenience translation rate of I USD = Rs. 75.53

Key Balance Sheet Items

	As on 30th Jun 2020				As on 31st Mar 2020				As on 30th Jun 2019
Particulars	($)		(Rs.)		($)		(Rs.)		($)		(Rs.)
Cash and cash equivalents and other investments		374		28,227		345		26,068		377		28,439
Trade receivables (current & non-current)		640		48,316		689		52,015		503		37,961
Inventories		518		39,148		464		35,066		465		35,137
Property, plant and equipment*		717		54,183		693		52,332		716		54,083
Goodwill and Other Intangible assets*		609		45,991		419		31,653		633		47,821
Loans and borrowings (current & non-current)		418		31,582		293		22,102		455		34,389
Trade payables		252		19,038		221		16,659		197		14,842
Equity		2,142		1,61,748		2,052		1,54,988		1,936		1,46,209

*On the basis of provisional allocation of purchase price for the business acquired from Wockhardt

Revenue Mix by Segment

	Q1 FY21		Q1 FY20		YoY			Q4 FY20		QoQ
Particulars	(Rs.)		(Rs.)		Growth %			(Rs.)		Growth %
Global Generics		35,075		32,982		6	%		36,398		(4	%)
North America		17,282		16,323		6	%		18,072		(4	%)
Europe		3,551		2,404		48	%		3,446		3	%
India		6,260		6,960		(10	%)		6,839		(8	%)
Emerging Markets		7,982		7,296		9	%		8,042		(1	%)
Pharmaceutical Services and Active Ingredients (PSAI)		8,553		4,539		88	%		7,195		19	%
Proprietary Products & Others		547		914		(40	%)		725		(25	%)
Total		44,175		38,435		15	%		44,318		0	%

COVID-19 Update

In the current challenging times due to the COVID-19 pandemic, we are undertaking reasonable precautions to ensure the health and safety of our employees, including adhering to the social distancing norms, sanitization of our premises, usage of masks, gloves and other protective wears.

Our operations have continued without much impact. We continued our engagement with doctors through digital channels, ensured regular supplies of our products to meet with the market demand and continued our R&D activities including few projects pertaining to COVID-19.

While the sales volume were impacted in some of our markets due to lower prescriptions generated and fall in patient footfalls in pharmacies / clinics due to Covid-19, the pricing environment was relatively stable, new products launches continued and depreciation of rupee against the US dollar and Euro supported the business.

Revenue Analysis

Global Generics (GG)

Revenues from GG segment at Rs. 35.1 billion:

Year-on-year growth of 6% driven primarily by Europe and Emerging Markets. This was offset partially by decline in India. The overall growth was on account of volume traction in the base business, new product launches and aided by favorable forex rates, though offset partially due to price erosion.

Sequential quarter decline of 4%, which is attributable to lower volumes across markets.

North America

Revenues from North America at Rs. 17.3 billion:

Year-on-year growth of 6%, driven by contribution from new products launched and aided by a favorable forex rate, which was partially offset by price erosion.

Sequential decline of 4%, on account of lower sales of certain key molecules.

We launched six new products (Fenofibrate Tablets, Nitroglycerin Patch, Amphetamine Sulfate Tablets, Desmopressin Acetate Ampules, Colchicine Tablets and Abiraterone Acetate Tablets)

We filed five new ANDAs during the quarter. As of 30^th June 2020, cumulatively 101 generic filings are pending for approval with the USFDA (99 ANDAs and 2 NDAs under 505(b)(2) route). Of the 99 ANDAs, 54 are Para IVs and we believe 28 have ‘First to File’ status.

Emerging Markets

Revenues from Emerging Markets at Rs. 8.0 billion. Year-on-year growth of 9%. Sequential decline of 1%:

Revenues from Russia at Rs. 3.3 billion. Year-on-year decline of 17% and sequential decline of 16%. Decline primarily on account of lower volumes due to lower prescriptions generated and fall in patient footfalls in pharmacies / clinics due to Covid-19.

Revenues from other CIS countries and Romania market at Rs. 1.4 billion. Year-on-year growth of 15% driven by higher volumes and new product launches. Sequential decline of 22% on account of lower volumes.

Revenues from Rest of World (RoW) territories at Rs. 3.3 billion. Year-on-year growth of 56% & sequential growth of 41%, primarily driven by new products and volume traction in base business. The growth was offset partially due to price erosion in some molecules.

India

Revenues from India at Rs. 6.3 billion:

Year-on-year decline of 10% and sequential decline of 8%. The decline was on account of lower sales volume due to lower prescriptions generated and fall in patient footfalls in pharmacies / clinics due to Covid-19.

We launched four new brands during the period.

We completed the acquisition of select business from Wockhardt including the manufacturing plant located in Baddi, Himachal Pradesh in the quarter.

Europe

Revenues from Europe at Rs. 3.6 billion:

Year-on-year growth of 48%, on account of new product launches and volume traction across markets.

Sequential growth of 3%, aided by contribution by new products launched and favorable forex, offset partially by lower volumes.

Pharmaceutical Services and Active Ingredients (PSAI)

Revenues from PSAI at Rs. 8.6 billion:

	Ø	Year-on-year growth of 88% and sequential growth of 19% on account of higher volumes of certain products, increase in new product sales and favorable forex.

During the quarter we filed DMF for one product in the US.

Proprietary Products (PP)

Revenues from PP at Rs. 56 million:

Year-on-year decline of 80% due to absence of the Neurology franchise products (the US and select territory rights of which were sold in the previous year).

Income Statement Highlights:

Gross profit margin at 56.0%:

Increased by ~430 bps over previous year and by ~450 bps sequentially, primarily on account of a favorable product mix and forex benefit.

Gross profit margin for GG and PSAI business segments are at 61.4% and 33.4% respectively.

SG&A expenses at Rs. 12.8 billion, increased by 6% on a year-on-year basis and by 5% sequentially. The increase was primarily attributable to higher freight cost due to shortage of carriers for shipping the goods from India to other countries due to COVID-19 related disruptions.

R&D expenses at Rs. 4.0 billion. As % to revenues- Q1 FY21: 9.0% | Q4 FY 20: 9.5% | Q1 FY20: 9.4%. Our focus continues on building complex generics, bio-similars and differentiated products pipeline. We are also undertaking development of a few projects pertaining to COVID-19 related drugs.

Other operating income at Rs. 118 million compared to Rs. 3.8 billion in Q1 FY20. Previous year included Rs. 3.5 billion received from Celgene pursuant to an agreement entered towards settlement of any claim the Company or its affiliates may have had for damages under section 8 of the Canadian Patented Medicines (Notice of Compliance) Regulations in regard to the Company’s ANDS for a generic version of REVLIMID brand capsules, (Lenalidomide) pending before Health Canada.

Net Finance income at Rs. 605 million compared to Rs. 393 million in Q1 FY20. The increase is primarily on account of higher foreign exchange gain as compared to the previous year.

Profit before Tax at Rs. 8.8 billion, increased by 3% year-on-year and by 23% sequentially. Adjusted for the Rs. 3.5 billion received from Celgene last year, the year-on-year growth is at 74%.

Profit after Tax at Rs. 5.8 billion. The effective tax rate is around 34% for the quarter. The higher tax rate was primarily due to discontinuation of weighted deduction on R&D and completion of tax holiday for one of our plants.

Diluted earnings per share is at Rs. 34.86.

Other Highlights:

Capital expenditure is at Rs. 1.5 billion.

Free cash-flow generated during the quarter stood at Rs. 9.3 billion (before acquisition related payout to Wockhardt of Rs. 15 billion).

Net debt of the company is at Rs. 3.4 billion as on June 30, 2020. Consequently, net debt to equity ratio is 0.02.

Earnings Call Details (05:30 pm IST, 08:00 am EDT, July 29, 2020)

The management of the Company will host an earnings call to discuss the Company’s financial performance and answer any questions from the participants.

Conference Joining Information

Option 1: Express Join with DiamondPass™

Pre-register with the below link and join without waiting for the operator.

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=122477&linkSecurityString=5070ddaf

Option 2: Join through below Dial-In Numbers

Universal Access Number:

+91 22 6280 1219

+91 22 7115 8120

Local Access Number:

Available all over India

+91 70456 71221

International Toll Free Number:

USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.

Play Back: The play back will be available after the earnings call, till August 6^th, 2020. For play back dial in phone No: +91 22 7194 5757 | +91 22 6663 5757, and Playback Code is 58336.

Transcript: Transcript of the Earnings call will be available on the Company’s website: www.drreddys.com

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues, (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein.

EX-99.2 3 drr0238_ex99-2.htm EXHIBIT 99.2

Exhibit 99.2

Unaudited consolidated financial results of Dr. Reddy's Laboratories Limited and its subsidiaries for the quarter ended 30 June 2020 prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB)

All amounts in Indian Rupees millions

		Quarter ended									Year ended
Sl. No.	Particulars	30.06.2020			31.03.2020			30.06.2019			31.03.2020
		(Unaudited)			(Audited)			(Unaudited)			(Audited)
1	Revenues		44,175			44,318			38,435			174,600
2	Cost of revenues		19,420			21,510			18,576			80,591
3	Gross profit (1 - 2)		24,755			22,808			19,859			94,009
4	Selling, general and administrative expenses		12,786			12,177			12,065			50,129
5	Research and development expenses		3,980			4,190			3,609			15,410
6	Impairment of non current assets		-			7			-			16,767
7	Other income, net		(118	)		(168	)		(3,759	)		(4,290	)
	Total operating expenses		16,648			16,206			11,915			78,016
8	Results from operating activities [(3) - (4 + 5 + 6 + 7)]		8,107			6,602			7,944			15,993
	Finance income		838			665			690			2,461
	Finance expense		(233	)		(230	)		(297	)		(983	)
9	Finance income, net		605			435			393			1,478
10	Share of profit of equity accounted investees, net of tax		77			105			163			561
11	Profit before tax (8 + 9 + 10)		8,789			7,142			8,500			18,032
12	Tax expense/(benefit), net		2,996			(500	)		1,872			(1,466	)
13	Profit for the period / year (11 -12)		5,793			7,642			6,628			19,498
14	Earnings per share:
	Basic earnings per share of Rs.5/- each		34.94			46.10			39.98			117.63
	Diluted earnings per share of Rs.5/- each		34.86			46.01			39.91			117.40
			(Not annualised)			(Not annualised)			(Not annualised)

Segment reporting (consolidated)

All amounts in Indian Rupees millions

		Quarter ended							Year ended
Sl. No.	Particulars	30.06.2020		31.03.2020			30.06.2019		31.03.2020
		(Unaudited)		(Audited)			(Unaudited)		(Audited)
	Segment wise revenue and results:
1	Segment revenue:
	a) Pharmaceutical Services and Active Ingredients		10,090		8,673			5,933		31,657
	b) Global Generics		35,075		36,398			32,982		138,123
	c) Proprietary Products		56		2			281		7,949
	d) Others		491		723			633		2,781
	Total		45,712		45,796			39,829		180,510
	Less: Inter-segment revenues		1,537		1,478			1,394		5,910
	Net revenue from operations		44,175		44,318			38,435		174,600

2	Segment results:
	Gross profit from each segment
	a) Pharmaceutical Services and Active Ingredients		2,856		2,043			325		6,190
	b) Global Generics		21,526		20,332			19,007		78,449
	c) Proprietary Products		56		(7	)		207		7,744
	d) Others		317		440			320		1,626
	Total		24,755		22,808			19,859		94,009
	Less: Selling and other un-allocable expenditure, net of other income		15,966		15,666			11,359		75,977
	Total profit before tax		8,789		7,142			8,500		18,032

Global Generics segment includes operations of Biologics business. Inter-segment revenues represent sale from Pharmaceutical Services and Active Ingredients to Global Generics at cost.

Notes:

The unaudited results have been reviewed by the Audit Committee of the Board on 29 July 2020 and approved by the Board of Directors of the Company at their meeting held on 29 July 2020. The above financial results have been prepared in accordance with International Financial Reporting Standards and its interpretations (IFRS), as issued by the International Accounting Standards Board (IASB).

On 10 June 2020, the Company completed the acquisition of select divisions of Wockhardt Limited’s branded generics business in India and the territories of Nepal, Sri Lanka, Bhutan and Maldives. The business comprises a portfolio of 62 brands in multiple therapy areas, such as respiratory, neurology, venous malformations, dermatology, gastroenterology, pain, and vaccines. This entire portfolio has been transferred to the Company, along with related sales and marketing teams, the manufacturing plant located in Baddi, Himachal Pradesh, and employees. The Company is in the process of determination of the fair value of consideration transferred, assets acquired and liabilities assumed. As at 30 June 2020, the Company, on a provisional basis, recognised Rs. 373 million and Rs. 14,141 million towards property, plant and equipment and intangible assets, respectively. The acquisition pertains to the Company's Global Generics segment.

"Other income, net" for the quarter ended 30 June 2019 and year ended 31 March 2020 includes an amount of Rs. 3,457 million received from Celgene, pursuant to a settlement agreement entered in April 2019. The agreement effectively settles any claim the Company or its affiliates may have had for damages under section 8 of the Canadian Patented Medicines (Notice of Compliance) Regulations in regard to the Company’s ANDS for a generic version of REVLIMID brand capsules, (Lenalidomide) pending before Health Canada.

Total impairment charge for the year ended 31 March 2020 is Rs. 16,767 million, of which Rs. 11,137 million was towards impairment of gNuvaring, Rs. 4,385 million was towards ramelteon, tobramycin and imiquimod, and the balance is towards other product related intangibles forming part of Company’s Global generics and Proprietary Products segments.

Tax benefit for the year ended 31 March 2020 was primarily due to recognition of deferred tax asset of:
- Rs. 4,989 million towards MAT recoverable pursuant to enactment of Taxation Laws (Amendment) Act, 2019;
- Rs. 1,264 million pursuant to a planned restructuring activity between the group Companies.

"Revenues" for the year ended 31 March 2020 includes an amount of Rs. 7,486 million (U.S.$108.7 million) towards license fee for selling US and select territory rights for ZEMBRACE^® SYMTOUCH^® (sumatriptan injection) 3 mg and TOSYMRA^® (sumatriptan nasal spray) 10 mg, (formerly referred to as “DFN-02”) to Upsher-Smith Laboratories, LLC. The costs associated with this transaction are Rs. 328 million.

The Company continues to consider the impact of COVID-19 pandemic in assessing the recoverability of receivables, goodwill, intangible assets, and certain investments. For this purpose, the Company considered internal and external sources of information up to the date of approval of these financial results. The Company based on its judgements, estimates and assumptions including sensitivity analysis expects to fully recover the carrying amount of receivables, goodwill, intangible assets, investments and other assets.The Company will continue to closely monitor any material changes to future economic conditions.

The unaudited results were reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 29 July 2020.

The figures of the quarter ended 31 March 2020 are the balancing number between audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year, which are subject to limited review.

The results for the quarter ended 30 June 2020 were subjected to a "Limited Review". An unqualified report was issued thereon.

By order of the Board

For Dr. Reddy's Laboratories Limited

Place: Hyderabad	G V Prasad
Date: 29 July 2020	Co-Chairman & Managing Director

EX-99.3 4 drr0238_ex99-3.htm EXHIBIT 99.3

Exhibit 99.3

Independent Auditor’s Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to

The Board of Directors

Dr. Reddy’s Laboratories Limited

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Dr. Reddy’s Laboratories Limited (the “Holding Company”) and its subsidiaries (the Holding Company and its subsidiaries together referred to as “the Group”) and its joint ventures for the quarter ended June 30, 2020 (the “Statement”) attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).

This Statement, which is the responsibility of the Holding Company’s Management and approved by the Holding Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

The Statement includes the results of the following entities:

SL. No	Name of the Company
Subsidiaries
1	Aurigene Discovery Technologies Limited
2	Cheminor Investments Limited
3	Dr. Reddy’s Bio-Sciences Limited
4	Dr. Reddy’s Farmaceutica Do Brasil Ltda.

5	Dr. Reddy's Laboratories SA
6	Idea2Enterprises (India) Private Limited
7	Imperial Credit Private Limited
8	Industrias Quimicas Falcon de Mexico, S.A.de C.V.
9	Reddy Antilles N.V. (till 02 November, 2019)
10	Regkinetics Services Limited (formerly Dr. Reddy’s Pharma SEZ Limited)
11	Aurigene Discovery Technologies (Malaysia) SDN BHD
12	Aurigene Discovery Technologies Inc.
13	Aurigene Pharmaceutical Services Limited (from 16 September 2019)
14	beta Institut gemeinnützige GmbH
15	betapharm Arzneimittel GmbH
16	Chirotech Technology Limited
17	DRL Impex Limited
18	Dr. Reddy’s Laboratories (Australia) Pty. Limited
19	Dr. Reddy’s Laboratories Canada, Inc.
20	Dr. Reddy's Laboratories Chile SPA.
21	Dr. Reddy’s Laboratories (EU) Limited
22	Dr. Reddy’s Laboratories Inc.
23	Dr. Reddy's Laboratories Japan KK
24	Dr. Reddy’s Laboratories Kazakhstan LLP
25	Dr. Reddy’s Laboratories LLC
26	Dr. Reddy's Laboratories Louisiana LLC
27	Dr. Reddy’s Laboratories Malaysia Sdn. Bhd.
28	Dr. Reddy’s Laboratories New York, Inc.
29	Dr. Reddy's Laboratories Philippines Inc.
30	Dr. Reddy’s Laboratories (Proprietary) Limited
31	Dr. Reddy's Laboratories Romania S.R.L.
32	Dr. Reddy's Laboratories SAS
33	Dr. Reddy's Laboratories Taiwan Limited
34	Dr. Reddy's Laboratories (Thailand) Limited
35	Dr. Reddy’s Laboratories (UK) Limited
36	Dr. Reddy's Research and Development B.V.
37	Dr. Reddy’s Singapore PTE Limited (till 04 June, 2019)
38	Dr. Reddy’s Srl
39	Dr. Reddy’s New Zealand Limited
40	Dr. Reddy’s (WUXI) Pharmaceutical Co. Limited
41	Dr. Reddy's Venezuela, C.A.
42	Dr. Reddy's Laboratories B.V. (Formerly Eurobridge Consulting B.V.
43	Lacock Holdings Limited
44	OOO Dr. Reddy’s Laboratories Limited
45	OOO DRS LLC
46	Promius Pharma LLC
47	Reddy Holding GmbH
48	Reddy Netherlands B.V.
49	Reddy Pharma Iberia SA
50	Reddy Pharma Italia S.R.L
51	Reddy Pharma SAS

Joint ventures
1	DRANU LLC
2	DRES Energy Private Limited
3	Kunshan Rotam Reddy Pharmaceutical Company Limited

Other consolidating entities
1	Cheminor Employees Welfare Trust
2	Dr. Reddy's Employees ESOS Trust
3	Dr. Reddy's Research Foundation

Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (‘Ind AS’) specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

per S Balasubrahmanyam

Partner

Membership No.: 053315

UDIN: 20053315AAAACC1821

Chennai

July 29, 2020

Dr. Reddy’s Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500 034, Telangana, India.

CIN : L85195TG1984PLC004507

Tel :+91 40 4900 2900

Fax :+91 40 4900 2999

Email :mail@drreddys.com

www.drreddys.com

DR. REDDY'S LABORATORIES LIMITED

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2020

All amounts in Indian Rupees millions

		Quarter ended									Year ended
Sl. No.	Particulars	30.06.2020			31.03.2020			30.06.2019			31.03.2020
		(Unaudited)			(Audited)			(Unaudited)			(Audited)

1	Revenue from operations
	a) Net sales / income from operations		43,244			43,361			37,624			163,574
	b) License fees and service income		931			957			812			11,026
	c) Other operating income		90			171			146			570

	Total revenue from operations		44,265			44,489			38,582			175,170

2	Other income		871			736			4,301			6,206

3	Total income (1 + 2)		45,136			45,225			42,883			181,376

4	Expenses
	a) Cost of materials consumed		11,439			7,453			7,364			29,848
	b) Purchase of stock-in-trade		5,276			5,875			5,216			25,459
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade		(3,519	)		1,983			(511	)		237
	d) Employee benefits expense		8,724			8,555			8,615			33,802
	e) Depreciation and amortisation expense		2,923			2,741			2,890			11,631
	f) Impairment of non-current assets		-			7			-			16,767
	g) Finance costs		233			230			298			983
	h) Selling and other expenses		11,132			11,124			10,481			44,353

	Total expenses		36,208			37,968			34,353			163,080

5	Profit / (loss) before tax and before share of equity accounted investees(3 - 4)		8,928			7,257			8,530			18,296

6	Share of profit of equity accounted investees, net of tax		77			105			163			561

7	Profit before tax (5+6)		9,005			7,362			8,693			18,857

8	Tax expense / (benefit):
	a) Current tax		3,166			417			2,355			6,616
	b) Deferred tax		(107	)		(866	)		(427	)		(8,019	)


9	Net profit after taxes and share of profit of associates (7 - 8)		5,946			7,811			6,765			20,260

10	Other comprehensive income
	a) (i) Items that will not be reclassified subsequently to profit or loss		207			(326	)		(47	)		(412	)
	(ii) Income tax relating to items that will not be reclassified to profit or loss		-			(22	)		-			(22	)
			-			-
	b) (i) Items that will be reclassified subsequently to profit or loss		731			(1,011	)		(269	)		(448	)
	(ii) Income tax relating to items that will be reclassified to profit or loss		(156	)		96			23			232
	Total other comprehensive income		782			(1,263	)		(293	)		(650	)

11	Total comprehensive income (9 + 10)		6,728			6,548			6,472			19,610

12	Paid-up equity share capital (face value Rs. 5/- each)		831			831			831			831

13	Other equity											155,157

14	Earnings per equity share (face value Rs. 5/- each)

	Basic		35.87			47.12			40.81			122.22
	Diluted		35.78			47.03			40.74			121.99
			(Not annualised)			(Not annualised)			(Not annualised)

See accompanying notes to the financial results

DR. REDDY'S LABORATORIES LIMITED

Segment Information

All amounts in Indian Rupees millions

		Quarter ended							Year ended
Sl. No.	Particulars	30.06.2020		31.03.2020			30.06.2019		31.03.2020
		(Unaudited)		(Audited)			(Unaudited)		(Audited)
	Segment wise revenue and results:
1	Segment revenue :
	a) Pharmaceutical Services and Active Ingredients		10,165		8,782			6,052		32,086
	b) Global Generics		35,092		36,460			33,010		138,264
	c) Proprietary Products		56		2			281		7,949
	d) Others		489		723			633		2,781
	Total		45,802		45,967			39,976		181,080

	Less: Inter-segment revenue		1,537		1,478			1,394		5,910
	Total revenue from operations		44,265		44,489			38,582		175,170

2	Segment results:
	Gross profit from each segment
	a) Pharmaceutical Services and Active Ingredients		2,859		2,050			332		6,219
	b) Global Generics		21,526		20,332			19,007		78,449
	c) Proprietary Products		56		(7	)		207		7,744
	d) Others		317		442			320		1,626
	Total		24,758		22,817			19,866		94,038

	Less: Selling and other un-allocable expenditure / (income), net		15,753		15,455			11,173		75,181
	Total profit before tax		9,005		7,362			8,693		18,857

Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics at cost.

Segmental Capital employed

As certain assets of the Company including manufacturing facilities, development facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Notes:

These results have been prepared in accordance with the Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules 2015 as amended.

"Other income" for the quarter ended 30 June 2019 and year ended 31 March 2020 includes an amount of Rs. 3,457 million received from Celgene, pursuant to a settlement agreement entered in April 2019. The agreement effectively settles any claim the Company or its affiliates may have had for damages under section 8 of the Canadian Patented Medicines (Notice of Compliance) Regulations in regard to the Company’s ANDS for a generic version of REVLIMID brand capsules, (Lenalidomide) pending before Health Canada.

Tax benefit for the year ended 31 March 2020 was primarily due to recognition of deferred tax asset of:

- Rs. 4,989 million towards MAT recoverable pursuant to enactment of Taxation Laws (Amendment) Act, 2019;

- Rs. 1,264 million pursuant to a planned restructuring activity between the group Companies.

"Revenue from operations" for the year ended 31 March 2020 includes an amount of Rs. 7,486 million (U.S.$108.7 million) towards license fee for selling US and select territory rights for ZEMBRACE^® SYMTOUCH^® (sumatriptan injection) 3 mg and TOSYMRA^® (sumatriptan nasal spray) 10 mg, (formerly referred to as “DFN-02”) to Upsher-Smith Laboratories, LLC. The costs associated with this transaction are Rs. 328 million.

The unaudited results were reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 29 July 2020.

The results for the quarter ended 30 June 2020 were subject to a "Limited Review" by the Statutory Auditors of the Company. An unqualified report has been issued by them thereon.

By order of the Board

For Dr. Reddy's Laboratories Limited

Place: Hyderabad	G V Prasad
Date: 29 July 2020	Co-Chairman & Managing Director

EX-99.4 5 drr0238_ex99-4.htm EXHIBIT 99.4

Exhibit 99.4

Independent Auditor’s Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to

The Board of Directors

Dr. Reddy’s Laboratories Limited

We have reviewed the accompanying statement of unaudited standalone financial results of Dr. Reddy’s Laboratories Limited (the “Company”) for the quarter ended June 30, 2020 (the “Statement”) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).

This Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (‘Ind AS’) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

per Balasubrahmanyam

Partner

Membership No.: 053315

UDIN: 20053315AAAACB8197

Place: Chennai

Date: July 29, 2020

Dr. Reddy’s Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500 034, Telangana, India.

CIN : L85195TG1984PLC004507

Tel :+91 40 4900 2900

Fax :+91 40 4900 2999

Email :mail@drreddys.com

www.drreddys.com

DR. REDDY'S LABORATORIES LIMITED

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2020

All amounts in Indian Rupees millions

		Quarter ended									Year ended
Sl. No.	Particulars	30.06.2020			31.03.2020			30.06.2019			31.03.2020
		(Unaudited)			(Audited)			(Unaudited)			(Audited)

1	Revenue from operations
	a) Net sales / income from operations		32,264			28,195			24,827			109,925
	b) License fees and service income		104			184			149			8,105
	c) Other operating income		76			138			111			474
	Total revenue from operations		32,444			28,517			25,087			118,504

2	Other income		6,447			1,274			4,714			7,432

	Total income (1 + 2)		38,891			29,791			29,801			125,936

3	Expenses
	a) Cost of materials consumed		7,882			6,543			5,839			25,565
	b) Purchase of stock-in-trade		3,003			2,261			2,479			11,172
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade		(1,929	)		672			(675	)		(999	)
	d) Employee benefits expense		5,450			5,166			4,996			20,302
	e) Depreciation and amortisation expense		1,977			1,923			1,970			7,892
	f) Finance costs		140			118			121			478
	g) Selling and other expenses		8,751			8,667			8,141			33,768

	Total expenses		25,274			25,350			22,871			98,178

4	Profit before tax (1 + 2 - 3)		13,617			4,441			6,930			27,758

5	Tax expense / (benefit)
	a) Current tax		2,391			690			1,528			4,839
	b) Deferred tax		1,724			(1,277	)		(79	)		(6,458	)

6	Net profit for the period / year (4 - 5)		9,502			5,028			5,481			29,377

7	Other comprehensive income
	a) (i) Items that will not be reclassified to profit or loss		(1	)		85			4			88

	(ii) Income tax relating to items that will not be reclassified to profit or loss		-			(33	)		-			(33	)

	b) (i) Items that will be reclassified to profit or loss		360			(464	)		(64	)		(750	)

	(ii) Income tax relating to items that will be reclassified to profit or loss		(128	)		161			20			259

	Total other comprehensive income		231			(251	)		(40	)		(436	)

8	Total comprehensive income (6 + 7)		9,733			4,777			5,441			28,941

9	Paid-up equity share capital (face value Rs. 5/- each)		831			831			831			831

10	Other equity											151,088

11	Earnings per equity share (face value Rs. 5/- each)

	Basic		57.31			30.34			33.06			177.23
	Diluted		57.18			30.28			33.01			176.88
			(Not annualised)			(Not annualised)			(Not annualised)

See accompanying notes to the financial results.

DR. REDDY'S LABORATORIES LIMITED

Segment information

All amounts in Indian Rupees millions

		Quarter ended									Year ended
Sl. No.	Particulars	30.06.2020			31.03.2020			30.06.2019			31.03.2020
		(Unaudited)			(Audited)			(Unaudited)			(Audited)
	Segment wise revenue and results
1	Segment revenue
	a) Pharmaceutical Services and Active Ingredients		8,706			7,373			5,617			26,996
	b) Global Generics		25,241			22,606			20,828			89,774
	c) Proprietary Products		34			16			36			7,644
	Total		33,981			29,995			26,481			124,414

	Less: Inter-segment revenue		1,537			1,478			1,394			5,910
	Total revenue from operations		32,444			28,517			25,087			118,504

2	Segment results
	Profit / (loss) before tax and interest from each segment
	a) Pharmaceutical Services and Active Ingredients		5,686			438			(424	)		1,465
	b) Global Generics		8,242			4,203			7,810			22,116
	c) Proprietary Products		(174	)		(97	)		(277	)		6,525
	Total		13,754			4,544			7,109			30,106

	Less: (i) Finance costs		140			118			121			478
	(ii) Other un-allocable expenditure / (income), net		(3	)		(15	)		58			1,870
	Total profit before tax		13,617			4,441			6,930			27,758

Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics at cost.

Segmental capital employed

Notes:

"Other income" for the quarter ended 30 June 2020 includes

- Rs. 4,772 million received from Aurigene Pharmaceutical Services limited (APSL) during the quarter ended 30 June 2020, pursuant to sale of the contract development and manufacturing organisation (CDMO) division of the Custom Pharmaceutical Services (CPS) business of the Company.

- Rs. 516 million received of preference dividend declared by Dr. Reddy's Laboratories S.A. during the quarter.

"Other income" for the quarter ended 30 June 2019 includes dividend income of Rs. 392 million declared by Kunshan Rotam Reddy Pharmaceutical Company Limited during the quarter.

Tax benefit for the year ended 31 March 2020 was primarily due to recognition of deferred tax asset of:

- Rs. 4,989 million towards MAT recoverable pursuant to enactment of Taxation Laws (Amendment) Act, 2019;

- Rs. 1,264 million pursuant to a planned restructuring activity between the group Companies

The Company continues to consider the uncertainty relating to the COVID-19 pandemic in assessing the recoverability of receivables, goodwill, intangible assets, and certain investments. For this purpose, the Company considered internal and external sources of information up to the date of approval of these financial results. The Company based on its judgements, estimates and assumptions including sensitivity analysis expects to fully recover the carrying amount of receivables, goodwill, intangible assets, investments and other assets. The Company will continue to closely monitor any material changes to future economic conditions.

The unaudited results were reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 29 July 2020.

The results for the quarter ended 30 June 2020 presented were subjected to a “Limited review” by the Statutory Auditors of the Company. An unqualified report was issued by them thereon.

By order of the Board

For Dr. Reddy's Laboratories Limited

Place: Hyderabad	G V Prasad
Date: 29 July 2020	Co-Chairman & Managing Director

GRAPHIC 6 drr0238_ex99-1img01.jpg GRAPHIC begin 644 drr0238_ex99-1img01.jpg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end GRAPHIC 7 drr0238_ex99-1img02.jpg GRAPHIC begin 644 drr0238_ex99-1img02.jpg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end GRAPHIC 8 drr0238_ex99-3img01.jpg GRAPHIC begin 644 drr0238_ex99-3img01.jpg M_]C_X 02D9)1@ ! @ 9 !D #_[ 11'5C:WD 0 $ 9 _^X #D%D M;V)E &3 ?_; (0 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M P,# P,# P,#_\ $0@ ,0#' P$1 (1 0,1 ?_$ )T $#! ,! M &"0H! @<( P0%"P$! (# 0 $" P0%!A 8! M! $# P,"! < 0(#! 4&!P 1$@@)(3$3(A0505$*,A9Q(R0789&A)39V MMA$ 0,# @0#!@8!!0 0 " Q$A!#$%05%Q$F&A$X&1L<$B)-'A,E(C M%?!"8G(&%O_: P# 0 "$0,1 #\ G\:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$ M:(C1$:(C1$:(C1%J[VN[D=?>EF.0R9G^[(U>(=O21M?@V*!IBY7"3%1N19A4 M:JT.,I.*L$G)5G9TR_"T0_S%CD*(".?'QILE_9"*GCR'4HF%+5_)[Q SL!FM M,ZFY/L=8(X%,9RPY"J51F5FH*E*+EK7&43;6PF.CR.1-:01$1 I3"7<1+UF[ M'(6_5(T.Z$^=O@B M!4K+%OG<%9716ZZBP,TSIR -VJRQVY$R-))JXXJQTG#OF MRS5Z@IL9NY04(;U+KSLL3X9#%(*/!NH2RB+G4+!&2,W!6JMS4-$+OVLK+Q,[ M%247&.HHO*3;2#]D[7:,G$<4-UR*G*9$/ZP#52UP-"""42DY%VWW#;]]PVUB M]2/]P]X2A5IE$RF*4RA"F.(@0IC% QQ#U$"@([F$ _;4][.8]Z*_4U!T1&I1 M6%43,(%*H0PB!A "F*(B!3<#" .^Q3^@_L/IIK<:(K3'^KB4P;@ "( ("( M(CZB'OL.VJES6FCB ?$I0J\IR&WXF*;B(E-Q, \3!MN4=A]!#?VU D8XT:X$ M]4H5=JZ(T1&^B*FX#[" Z(JZ(K1,4/43% /7U$0#V]_^6IH4HJ@8IO4H@8 $ M0$0$!V$/00]/U =1IJBKHBIN >XAHBKHBL4432(=14Y$TTR&44.H8I"$3( F M.V65,LSDX^DZA'V:>IN'8APQ:YVTE!6&$>)2$1+,%R"!DG3%Z@1 M0H^P[;" @(@,$!P+7"K2*'HBEK>5FMYB\@7BQZ8=O*/6']CE:="Q^48\3/EQW&@ M)H#T-A7Q'FBB)QJ2TU(L(>%0<3,Q+/6T;$P\.@K*2TK)/5BMV4=%QK CA[(2 M#QP %).\K4RZY8=7F\8YC3,)-)0\^E2I<47[=(YUG14W+$J9SJ@4?,C(QY-V]9 M]/1K0'A4"@/OT]ZA-*^*_KWVOK>&_)=-O,9Y5IV%I_H/V)I[VN6.G6>!;W_+ M58U?J_BJ>6:R4P9&OQ*&3++-HQD0\4CER.6<7,G3 M2%%P1,QW10^%,'*?ZB(:?^9VZ@H\:>"!RW7Z@?R *=DK)K#$7:'%P8+G+#-- M(&OVM@_L+RK,IR4!%NPA[O%6Q)&>IQEWAA*"QS"@ &(/H \M:F7_ -7$<1R, M;ZXFZ_/P2JD@FD4TRDV3.L8Z(J$2;B1510Q4P6%,@ ?X_5$0,41. & 0VW'7 MF:".;TP;40KD3D$5"E'8Y#F(504C@'R%Y (@GNF*B1UPV]2%,)@_7WUG4)K; MRP=W,@]#NN%=RYBVM5*P6*?RU$4,6UT:/G<0S82$/8IR0='1C)&*<@;_ +"? MB;YMB&. B4?7;)@QB0]I)'13HF+VWG$\G+^BQV84NK%">8<.T7E7=T1QAD?^ MU%X=JJX3>2B-D0MBR*;-H5LHZ9U9-*G6BR-)-T_ M9XT_)!0_(/C>7G8N!0I>1<>R+:'R)24IIG*<1*H44A,58/B6 M-\8A[<3 ELJ4?W+N&N>L2YCK 4H"!3GW$ "@'IN CR,(CL4@;>HC[:(NN+L MH$%10O *<=]Q,G](;AR6*3XB@;?W$=M6:*BRL-%';\/'DQ[.=T^QF?\;YQ4 MH+VK4&C*VJH)4ZI!6GL4\)D4]558KJ_D9 9)G^+62$%%#@IS(8=MA#6>5C6L MJWB5"D5F6]N":BV^PB*8I?3OO_5S5((>VM90HZI_)EV/4\T3CHT1M27>!'%V M3HVZ=2(G:F?+"TC?9%=>UFE"*(*DDDTOA)]L<' ;E 0#WV^UHB#N(%5*D+M' M:*')!0!2."G)0JABE."JY2G233* F!8ZH#Z 41'?TUKO()MI1"N^=\W3,4BI MC)G,) X_&H<""?\ IYJ)D,F0O[F$0*'ZCJBA1V>F'D;[V9A\K&9^I6:<55'52CJP1M.8F@:FX:*X\MRM;LS?1Z8G.!F[L\PDLU(DD02 MAVNM=13A3Y(I& #OZ;"'^(:XR+HR<>E*L'\:X,18NF M"YDA*"I47B"C=4R8G(<@*%(J(AN AO[@.I!H:HOE>YNQ-9,#9CREA:WM%V5B MQ=?+-2I!-=,R9G!(64<-XV42 Q2?(SFXGX'K=0H<%4'!#E^DP:]W%(V6-LK? MTN *E8OUD1&B*31D#RH9LZ/^/[QP87Z]1ENMD?D:Q9#ML$G9FL56V]O MG:_%U^MP;I9*,7E))]&.SOG#D%0;-@1*D3FM\B?$9@QY.5-),3V!]*"W :_) M 32B66$O*,S4\=G9+LZKULZ\UWN#A._4?&U9RE2\,TV!CI*-21 M2ZS6PUO\=)KO6B;D[9ZY:MCF(FFY,F6)<'[MD'>\X[@207'_ $ZCH;=+I91P M[9V#SW>[\OE2X9KRM/9(SJ_V=*P,W"CH'O"(>LY-L,$Q2<@!DFK( M&[5$"E*FF4I2@'8;#$QGIM:T,Y4"*75X^_(=FOLCXKN\\Q>[[+O.Q'5C"V8P MBLH,VR$;8W,4MA2TV7%MQ=/VZ)6;NZ0\U77R:SL$@4649(KK%%10QC^=S,.* M#/B#!_#(X6X?J%1TNH3:G\;F**GWIRD:5%.078=7;L*+E;@H#<'64\4MC*F- MZD^1XF50@J&^I78P;CL.MC0!!=3DN";HP ;B78,^P[ MAF$28+GDXH:74(&MN-*^RM%C[42,F)1(Z*J!A YBE$.?MF'C9?JSY#>Z1K MJ U(XG@" B=N\6$'Y19_*DYGCN?;9C_:7(^,$G%-H,A8HQ1M$S;V=KTC"/(^ MD1T*S+744JR\<$$5%"+&.<_RD$2$$-/.CAB<6Q6(\:_%$C_Y(H 7I'CLY4RF M31[*THXJ*D<*M6RKZGY#8?.[1;B)W"'R.>(I#N4YAVV$=M-L8WO4E-"8'\W: M.'?']4NG[/ 3RU6BMXBMV+W>0']HCV5*63G$[2@69,[BQQ#0=/$ "W&ZLVE$K>C(YN\273#L3W5RC0'T#D/-1 M\98/ZW8[M;$C1\\504LDP\O-KK+==F=G IK\W#9(PD=KLV8&./%0!UYQV1'F MY0VZ,'U15VIN #7P5C>RP[$9D[Z7S$TCW$F?)G4*]:Q0G[VA@>1S7)U"VSM? M;O!0:I1%$CF9*Y67SEJ5,64-\2HCN B!S'UZ+"V[;!09<7'4 M?IM4R 4C83 4 ,(ZYO\ 78\F^'!:.W'UI-:+CUC%%K,Y5G#IJ+1BD^%$RY]_K M-N76]B_T,+)8,MGW'KN#35UFV !O36NMU%Z)%_Q_\ILL59C[O9>NJIOQN.NJ ML[>;6JU!!LFF:#R$C,R;,2/!_P!.]<+-%2%Y""8"!@#V#;C[Q!2-HQ1VDR < M[>VJEMS0KWL49=\M?EMOF3,F8+S9,85Q[391@6/B(>[S&-\;UA*33%W7ZT1U M#,2RU@L1F;@IY([O[A9,YP+N!2E .G-A[9B8#))V?<.'-USKI6GDK]HHL"]- MBYJ:> K&;&*J.X#RUCW+%@CV)F5 *3N1-%-!2JN;5@*^1KHK1,C8MQCD30;UL@9&O\ 6?KGF&YTKK[ABT.8 MK)3:F.F;"$D(S$3I,F69F0%1B+YXM)VMW^ 3164%N0J:9B%!14#'J<>&/:R^ M0?>=XH;Z=-/)57?\P]RL'C2C;#?>J;BX53-GD$RK:K'FG/LL^;V2T5^NX]KT M4G#8FQL^DVQVM/CS'GSK,?B1%PU:MU@27$2H&;;.VM&:0S(H8H6CM;H*DZGG MXJ5K)T=D/)PAFG =OP!WXQCW5JUQ-69'->*)KLVVL;ZCU([V.5N,);<>Y=>H MWYG*0T2\<&0EJTQ5U'7B 5D.PU*A&["]4A@"9%\R42%04^U/%)B M0#.:*$6HFJ@JL@NB MLW<-UEFSELY14;N6SENH9%PVMGY.Y".KJ5@9'>*& M,B;@XY(D6!-;X]=^5"R=N,XGU7"UK?Y9%*4H?6OHKG#PU]-+_KV;)76J:RA9XJP8NREFRN(+ M?[C9QBI)!U3)"TVJ-L,TZ7=2BC)&-38R18LAF2_VK$I'/QI#L/9N,$XSINUX M:+AO!O&@I\/;91P3/D]XB_)# Y!6B'2:L:F5D=,2ID$_,P#N :]!F8<&2VC]7[PMT\M3?=;ST9LQQ 0>&WN%,$8G?/3JSJZJDG7*F><529SUFDIF39Q3>6 MO;NL+G0BHM%!0/E^OF0HF$.-#V;-E.[GB9KX[%EJ5KK54<0=%DSS^X1AL22_ MCWQ[CF!O4FL#6K#0DHDBRS9F\54>R'QER6/YV\Y-P;=K?3'3.56+3IBSTNTNGT/(E;,W4BP:)3$D1(!6('QG H M;@(ZG%D$#JF].2BJT_S'X_&.:?")T_S31<>N&.#DF@-F[V6L$<@#*8BC+@+H3-3)IB +F >D-XR&N=&PN&,ZGTDZ&@TX" MM#IQ5FNH*+U(PN:/*MXA28::Q]ML/:3I3D2GR(1$@QD(Y[FBJPL%,PD$5D_F M6;!O(2LK2+ *"QN8 629&]>)BB+;)L''W,94K"*L<*V%R.?XJ0\#2J;EQUE# MH1B["JF,NPWCQO,[VOJJ$]6VTNM=[U4$KC-,7KI!@YR'6"SL4:%D(!=LC\Y& M2*@KM4T3)*&$=@Z&9ZF1,7PO#8B!8Z@]1SUNG??1.[85Z#Y"[(^(/+]N- M&ZV9;RG;J;F;&D%6I"XLI'*@XM(U-39W(L)=;%:)"O2UBBTG+9-C]R"!Q,F8 MQ"@8=]%F?'%NYSW!Q92E+5%J=/R5?@M9^E7F$OW2?JRATZL76/(5DS)BJ3N- M:QF7XOPJGW,S-3LE$-KI7GA2OWCR"F9(0428%%)RU(02>H@(X3MTF?D/RVSQ M11.>?I<#W>5J&FHIG'V"=N%@ M;J(?,Y8-BG*1V](O]!AXH@("&^M[+9%BPQO>]LG;(*AO0WNI!H:E7='.]&6_ M#R^S+@'L=U\NCY*;NP65E#Q\@RB)-K;HV*;U4SVO#('3C;/5[;!L"NA.0QCE M7 @D#<#[;&=AC?H&C%D;"X-[:NOR_;?@K=XT7A].;[E;L9YQ,5=@KYC*QT][ MD')<_D):"D8&2:M:I276"YR,HK=N^=1K8BQD8A$%UUCF YA5X?IMK%G/9)L[ M+4 M+E$-PV]M$4;+S#>%YOG_ /N7M-U.@&['/!432>2,41:+%A&9L$BB0.;)!&<. MF+"%R>W:BP0/68 M^!%,RAS+F15%5,$T_P#-$ UV9\B&&(R/([:&EQ>V@YHOI[A^X?KZ_P#0->'4 M*NB+'$5B'%T(+0\7CZH-%F+1=BU=%K\H &_M MJ[ YHHXU*J5U)"M5^5(W3E(6-E"-#/E$$GOY)%"3:)2"*+\/DXO$DGA%B)."?*; MB8H )0'TVU;O//@ILNR[AHJ0:KL9"/:R#-R("NU?I%>MU=C@H0ITG(*D$B9@ M#@&VQ-M@V#5*G1528MK>(C*V\0,1DR8KN8INHFJ9)!L87<@U8D0 %#%3**Q3 M FF0NWJ( 4-]7:>:A*AO#Q;-/XVK%NW3^,J1BHI@F"B1/Z$U>.PK%+^@&WV_ M36,O+152$GY7'M#G'J,E,TVLRDBW<(NT7[Z#C7+TCA -DE =*MC+CQ#TV$VP MA[@.I&5*!0%U/:I2G%J@(E'X2 ) *!=B\=BI@()E "[!Q2W'@'L4?4-AU;N/ M-6LDZ>BTM64/.*5*MFFU')'AY@T''#*F>$(5,KS\B+87@._C(!?D _,0 W] M UKRLD>ZK7D"BBR]@D/&(JJKH,F[=91_MK\D JO5"#AOF3( >FI&3)31WFB8 \OG1#MWWSSA@6@4.%C&G5ZG MQ0JW&T!>(>)G(^RW.=+&6V?CJ_(-UG#N4JE+C4OQYOJ(*KP_ H')R#=@E:6% MSK%0GXZ%1:UC>H52AU"*0B*Q2Z[$5>O1R!!*DQB(2/;QC% G(3&$P-VX"8PB M)CG,8QA$QC".-SB1]WZB3U*)< ![:JBKHB-$3&7E+\,F..Z$?-9AP MDW@,7]J$4TW*\L@/D-QM >-B'J_;2'Q=1NME(BH3LIAZ*/-24!> M%B7.0LTC%QZ<;'-H6]%<561)704D19%8F: _;J+*JF+J9,O#>9RZ,N>\_2>5 MJ>R]_)$^^9%(P;&(&PB CMN F$/83" @)MO^.N4BY=$1HB-$1HB-$1HB-$6( M,V_^$F_]GH?_ -C$Z(LOZ(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$ (:(C1$:(O_]D! end GRAPHIC 9 drr0238_ex99-3img02.jpg GRAPHIC begin 644 drr0238_ex99-3img02.jpg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drr0238_ex99-3img03.jpg GRAPHIC begin 644 drr0238_ex99-3img03.jpg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end GRAPHIC 11 drr0238_ex99-3img04.jpg GRAPHIC begin 644 drr0238_ex99-3img04.jpg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end GRAPHIC 12 drr0238_ex99-4img01.jpg GRAPHIC begin 644 drr0238_ex99-4img01.jpg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end GRAPHIC 13 drr0238_ex99-4img02.jpg GRAPHIC begin 644 drr0238_ex99-4img02.jpg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drr0238_ex99-4img03.jpg GRAPHIC begin 644 drr0238_ex99-4img03.jpg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end GRAPHIC 15 drr0238_ex99-4img04.jpg GRAPHIC begin 644 drr0238_ex99-4img04.jpg M_]C_X 02D9)1@ ! @ 9 !D #_[ 11'5C:WD 0 $ 9 _^X #D%D M;V)E &3 ?_; (0 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M P,# P,# P,#_\ $0@ ,@ X P$1 (1 0,1 ?_$ *8 (# 0$! M <* 8("04$ 0 !P$! @,$!08'" $0 & 0,# M @('!0D $" P0%!@< $0@2$PDA03$R47$B(Q0X"F&!L5)#0C,D-&05 M-646$0 ! @0$ @<%!@4% ! @, $00%(3$2!D$346%Q@3(4!Y&AP2)R M\+$S)#05T4+")0CA8H*R(__: P# 0 "$0,1 #\ ?I=R;)BB[P8Y3")%R)*E$Q1 !#?4A=[ M=6V.J:I+DVIMY\$IPP(''L/ \8)3U;-4)M3EUP0CKIIE.N2^&^4M/E;WA.UI6VM0ENLM(DGA M6KADHVL%4E%XF5;*-G12+E2%RW$R*@@!5DA Y?0=3%^L5QVY7(M]T2$U"V$. MB1F-"\L<,1D1P,,Z&X4]Q;+M-/2E4C,2Q@\&^4VWQZ1_AJ&F$XG(0^F!BGK?_5#:M-L MC=";53*4JAJ&6ULDG4HZFP5ZL!*2M0&>$H:6RI\Y1I?'$D=&1(CU?(=87Z>" M76+J]84:[:N05ZI.#80_94?2$CB08 'A]H#/&6,^1M/C M927FX>M\H[K3HF6F7#-1=PWI5/H\(Z;HMFAQ(T;1$J#F.VV^VJR4.([FU:/6 MR_VV[[AMBJ-*4J%"@* RU$*5]Q@EE!Y9EEJ'NCJ]9#]%?L1M@'IA98WJ(@'V M8M<=A$HE,'[A =9;0 ^82DG$.I]ZA$LL?^=1]/PA8?C#+)OE-]0_PUS]*>$6E?@/88IMU:I2%4L$JTO-0 MJIW3:'C_ #4B?9725@>-6"\\DZR^3\HV>PL53 ( (%)$&0*3Z0U >K5.FLW4J@;RI"VCL#8_UQB6V\K3: M4'B1'2Z6;%>1$HS$.H'D<^:B7Z?Q+=1#;?VWZ]55A7E:E52<)NH([0$@>\0[ M=F:$_2?C"J?ZPQ1LB3S2K46V6B0,=..K-BW4TZ5 @ MF+UF[+$0*4/F,(!Z (B"U,CF7&G1*>IT#VF$G?T!^@POM^G7LBYL&6!0! .@0V]?;;/7:C_O5HJI?* M:0 ?\4G^,5?:*CSW0V-4HE+L"A +O\ -/MN65/D-G(45>3JJIZL>QS6PXLITG@ MD);&$CF>F"W5SEU-0_AS5-Z,N$Y8=& .4,'<-: XQ;Q9XZT)TD@V7JN&,?PB MS9JF"*"*C&$:B!2I!\I^EQ]Y[B?<1UDF^*IJOWS<:RE)-.M]R1/4HC#O&'5* M+'9&@BU-CCI'O$XTNHD50ATQ$P%4 Q!$H[& -]MRC["&^J95J"J-4C@E:9'K MU#XP]0@.,%I7AQ'MG"F_C1"5H/FHY)X[)H@],XSW;R^3N>II1^' MR>_!0.<-A-G*BB'5]D"B4@D';U%(^PE,;U^)DQWURV^'"PE=+XYB<\<)_-[H MT>K#+* 1/2<#&+O(GE%OASA7R+OKQ^E''C<:SD2P?&3!4A)&VE1J$8@9$P[* M@\>SB:0@._S;^VK!L:E:ON_Z.T.@^3$G%$&1^6:E2/6 0.N(+6TC#IDVG&>.)XQ![8 M+C%>XTOQ%"5=Y$_C&'O*JC(UOG!R%PTY[:$/R\NGC_G6YC=7>D86NV5Y49]D MTW( "X),MDRF(41#MJ@81#X:L^QZEF]>E-KW13 !FPTMR9?2?Q-3R7>2M*<0 M4I+J2LE0T@$@&4%OA2FM\L?Q7%) / %1EGT8B' D56\6T,JY52;,X]-)$3J' M!,C9)%NCUD544Z$R@38-QWZ0V$1$ #7*JU/+?KR( MN/PH-^TF8>H#" [:B*&FKZQLVSD/)JU."6H2!FH$# DSEU0HX\U3-%QP@ISP M^PA.?@?G!IEGSO6?,S-.3+4L[P&;5*"9['K-9.:I["LD_P!CF$HXW4J>/D$J MNNJ@=,5.XB!3@&PCMU]OBA='I)2TB&USHVFDKRDG%(G.>1)D"98D1D=%4KO'KD=G1$N/4ZI>,[\C9.-">QDAD&#: MBG4^._0QRR1D0$IP3* M2P[$ !,.Q M##Z; ^N5E;=O2!":]2/,4=U?)E.6A]SF-R,IDS4K5, D 3SAHSRV=Q.)2# MBTV.\) C._DPJIN6/D4XS88PPTJ<'R"XVS9,B.[3?)%-Q29V#4A6-\K=9GXN M((><3(G-Q!1(/J=(%3'+MU!JX^FBV]D^FETO=T<2NR7-9I@T""L%P*;4K3.? M\TQAP..,0E]:/?% M=_/PC:S]*1D5$+MD^9!"QNHAT)Q7_"-NT.^Q#'Z=PUF[&Y[#M?2[8V>?6(&# MCJ)2F."9S[0"!QGPBP*M%1;43JQ,'?[A'$"7LU<@R&!)),Q^MJ2C89 MN+N;FD:L $]$SX1!&K/5I>_,.%3 R3C\JD8+1K:,7>QZ)78)L(QRJV0,@8BI$5CE'<##IA3^J&\; M?;ZBU-?F*:K)"P[\PQ4')R/0M((' Y2B3KJ"D=:0EM 0XDYI&)$B)'*-MX8P M5BGCUCFMXJP_3V%'HU::G:QL+$D,F457"G=>24BZ.)WDI,/W!SJ+NG"BBRBB MAC";<=5&X5-;?4G]R4>8%)(QG+2=4D] GF!G#^EI4,-Z42P'P@Q&;D,*>YC] M*8; 01 Y3>GH)NX4YA$H^H#O\0TG,F/8R??.*^/+?RKP_P K'DA8&&2\0TZV MT>";Q\@W0@)>"N"#XCA"PL%$C.WBC=Q(N3HBDH/L:FJ7<;]-MRX6)( M2IETI5C.8( 5,"4CD.,,ET255/FQ(*D![.G[92CR)C\VD-^5;_AE/E_-'_DF D_P#=_P#0?S_Z?IU##CV0]C9^BP(FA B:$")H0(FA B:$"/_9 end